Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma
Condition(s):Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell LymphomaLast Updated:January 30, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell LymphomaLast Updated:January 30, 2024Recruiting
Condition(s):Recurrent Glioblastoma MultiformeLast Updated:February 23, 2024Recruiting
Condition(s):Prostate CancerLast Updated:November 8, 2023Recruiting
Condition(s):Cardiovascular DiseasesLast Updated:February 4, 2022Recruiting
Condition(s):Stomach Diseases; Small Intestine DiseaseLast Updated:October 6, 2021Unknown status
Condition(s):Chronic Pain; Liver TransplantationLast Updated:January 22, 2024Recruiting
Condition(s):Early Detection of CancerLast Updated:May 26, 2023Recruiting
Condition(s):Type 2 Diabetes With Renal ManifestationsLast Updated:December 17, 2020Unknown status
Condition(s):Finger InjuriesLast Updated:October 24, 2018Completed
Condition(s):Soft Tissue Defect of Digit; Nerve InjuryLast Updated:October 15, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.